💊 Lupin 💊


📊About:
❧Founded in 1968, Lupin is an Indian Multinational Pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceuticals💊 by revenue globally. It employs 20K+ members from 11 countries to enable the safe delivery of medicines to patients across 📈100+ countries.
❧Lupin has a 4.04% weightage in the Nifty pharma index.

📊FInancials:
❧ In the recent quarterly results, Lupin posted a net loss of Rs.512 Cr due to rising costs📉 and price erosion in the US and an impairment expense of Rs.126.7 Cr📉 for US-based Gavis.
❧ Lupin posted a profit of Rs.464 Cr in the same period in the previous fiscal year.
❧ Sales of the company were up by📈 2.8% to Rs.3864 Cr while the EBITDA was down by 63% to Rs.282 Cr.
❧ Global API sales were down by 28%📉 to Rs.99 Cr in FY 22 compared to 138 Cr in FY21
❧ The Company has 📈53 FTF (First to File) filings including 21 exclusive FTF opportunities.💊
❧ Over the last 5 years market share of the company has decreased from 7.89% to 5.87%
❧ In the last 3 months, mutual fund holdings increased by 2.45%.📈
❧ The stock is having a PB ratio of 1.99 with a dividend yield of 0.66%.📈

📊Technicals:
❧ The stock is moving well below its 200 EMA and 50 DMA levels.
❧ After the significant fall in the last few trading sessions stock is nearing its key support zones between 560-580.📉
❧ In the last trading session, the movement was indecisive.
❧ A bounce can be expected from these support levels.
❧ RSI is at 24📉 showing the stock is oversold. Hence we a bounce can be seen.

Disclaimer: The information mentioned above is only for educational purposes. Kindly contact your financial advisor before trading/investing 💰

Please post your views/queries in the comments below. 👇